Lyell Immunopharma Inc
LYEL
Company Profile
Business description
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Contact
201 Haskins Way
South San FranciscoCA94080
USAT: +1 650 695-0677
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
300
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.00 | 177.90 | -1.96% |
| CAC 40 | 8,130.68 | 101.81 | -1.24% |
| DAX 40 | 23,758.01 | 283.61 | -1.18% |
| Dow JONES (US) | 46,934.25 | 522.97 | -1.10% |
| FTSE 100 | 9,660.57 | 250.85 | -2.53% |
| HKSE | 26,572.46 | 350.27 | -1.30% |
| NASDAQ | 22,648.06 | 222.29 | -0.97% |
| Nikkei 225 | 50,376.53 | 686.78 | -1.34% |
| NZX 50 Index | 13,464.46 | 207.27 | -1.52% |
| S&P 500 | 6,682.96 | 54.53 | -0.81% |
| S&P/ASX 200 | 8,634.50 | 164.90 | -1.87% |
| SSE Composite Index | 3,990.49 | 39.01 | -0.97% |